Strides Pharma Science Limited — Important, 29-04-2025: General Updates

Strides Pharma Science Limited's U.S. subsidiary has acquired four approved ANDAs from Nostrum Laboratories for approximately USD 2.075 million (around INR 176 Cr). The acquired portfolio targets treatments for UTIs, pain management, allergy symptoms, and attention deficit disorders, with a cumulative market size of around USD 57 million. Two ANDAs are commercial products expected to launch within 12 months, supporting Strides' strategy to enhance its niche and specialized product offerings.